FemPulse Announces Issuance of Patents in China and AustraliaHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)FemPulse Announces Issuance of Patents in China and AustraliaGlobeNewswireJanuary 6, 2020ReblogShareTweetShareMINNEAPOLIS, Jan. 06, 2020 (GLOBE NEWSWIRE) -- FemPulse Corporation (FemPulse), a private, clinical-stage bioelectronic medicine company developing a novel therapy for the personalized treatment of overactive bladder (OAB) in women, today announced the issuance of two patents from China and Australia covering methods of stimulation of autonomic nerve plexuses in women.The China National Intellectual Property Administration (CNIPA) recently granted Patent No. ZL 201380041407.2 to the Company. The issued patent, “Devices and Methods For Stimulating Nerves,” spans 134 claims and encompasses claims similar to those contained in three U.S. patents granted to the Company related to the vaginally-inserted technology. Additionally, The Australian Patent Office (IP Australia) granted the Company Australian Patent No. 2018200589, also entitled “Devices and Methods For Stimulating Nerves,” encompassing claims regarding important aspects of the FemPulse wearable therapy.“We are proud to see our intellectual property portfolio grow and support laying the groundwork for long-term market protection,” commented Donald Deyo, President and CEO.  “Both China and Australia represent tremendous potential markets for our therapy. The issuance of these patent serves as yet another validation of our cause to make bioelectronic medicine therapy for OAB available to women worldwide. Our device technology, which is based on proven bioelectronic medicine, is increasingly being recognized around the world. The granted patents further position FemPulse to be able to operate globally as we continue to advance product development.”The addition of these patents increases FemPulse’s domestic and international portfolio to seven issued patents.About FemPulse CorporationFemPulse Corporation is a privately held clinical-stage bioelectronic medicine company focused on treating women with overactive bladder. The company is developing the FemPulse System, an elegant neuromodulation platform, intended to provide mild electrical nerve stimulation to regulate bladder function and relieve the symptoms of OAB. The small, vaginal ring is disposable and may remain indwelling for days or weeks, affording discreet, personalized, continuous and self-managed therapy. For more information, visit www.fempulse.com.Investor Contact:Emma PoalilloThe Ruth Group646-536-7024epoalillo@theruthgroup.comMedia Contact:Kirsten ThomasThe Ruth Group508-280-6592kthomas@theruthgroup.comReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextKorea Cases Top 2,000; Nigeria Confirms Infection: Virus UpdateBloombergChina's February factory PMI seen at lowest since 2009 as coronavirus slams production: Reuters pollReutersFed seen cutting rates amid virus threat, low inflationReutersBaidu Becomes Latest Tech Giant to Deliver Disappointing OutlookBloombergNigeria confirms coronavirus case, first in sub-Saharan AfricaAFPBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceMost face masks won’t protect you from the coronavirusYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance Video'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo Finance